Aoti

Aoti Equity Ratio

The Equity Ratio of Aoti (AOTI.L) as of Oct 16, 2026 is 34.98 %. In the previous year, Equity Ratio was 44.11 % — a change of -20.69% (lower).

Equity Ratio

34.98 %

YoY

-20.69%

Last updated:

Equity Ratio of Aoti is 2025 34.98 % . Equity Ratio of Aoti was 2024 44.11 % . It decreases by -20.69% lower compared to the previous year.

The Aoti Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2021
101.00 USD
Jan 1, 2022
8.13 USD
Jan 1, 2023
-28.04 USD
Jan 1, 2024
44.11 USD
Jan 1, 2025
34.98 USD
The Aoti Equity Ratio history
YEAREquity RatioYoY
34.98 %-20.69%
44.11 %-257.32%
-28.04 %-444.85%
8.13 %-91.95%
101.00 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Aoti Stock analysis

What does Aoti do? Aoti Inc, trading under the ticker symbol AOTI.L and identified by the ISIN US03690C1027, is a United States-based enterprise headquartered in Oceanside, California. The company officially entered the public markets through an initial public offering on June 18, 2024. While specific sector and industry classifications are not provided in the available data, the firm’s operational focus is clearly defined within the medical technology landscape, specifically specializing in wound care technology on a global scale. The organization’s overarching mission is centered on empowering individuals with chronic conditions to regain their independence and improve their overall quality of life. This goal is pursued through a strategic commitment to enhancing access to essential healthcare services, driving improvements in clinical outcomes, and actively advancing health equity across diverse patient populations. Aoti’s approach to medical innovation is grounded in the belief that its products must be built with integrity and supported by robust clinical evidence. This commitment ensures that safety and efficacy remain paramount for patients relying on their solutions. The company’s portfolio is anchored by two primary therapeutic systems: Topical Wound Oxygen (TWO2) and NEXA Negative Pressure Wound Therapy (NPWT). The TWO2 therapy represents a multi-modality, patient-administered treatment option that has been clinically proven to effectively treat chronic and difficult-to-heal wounds. This system is designed to be accessible and manageable for patients, facilitating better adherence and outcomes in home or clinical settings. The NEXA NPWT System complements this offering by providing a multi-week, multi-patient, disposable solution. It is engineered to deliver the performance and flexibility associated with traditional NPWT systems, ensuring that healthcare providers have a reliable and efficient tool for managing complex wound care needs. By combining these advanced technologies, Aoti Inc aims to address the significant challenges faced by patients with chronic wounds, offering solutions that are both clinically effective and patient-centric. The company’s presence in Oceanside serves as the hub for its operations, supporting its global reach in delivering innovative wound care technologies that prioritize patient well-being and clinical success. Aoti is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Aoti stock

Equity Ratio of Aoti is 34.98 % in 2025.

Equity Ratio of Aoti changed from 44.11 % to 34.98 %, representing a -20.69% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Aoti since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Aoti with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Aoti

All Key Metrics — Aoti